Cost-effectiveness of using amyloid positron emission tomography in individuals with mild cognitive impairment

Autor:	Joon Hyuk Park, T.J. Lee, Hyun Ghang Jeong, Ki Woong Kim, Young Sil Lee, Ji Won Han, Hyun Chul Youn
Jazyk:	angličtina
Rok vydání:	2021
Předmět:	Gerontology medicine.medical_specialty Amyloid Medicine (General) Cost effectiveness media_common.quotation_subject Health administration R5-920 mental disorders Medicine Cognitive impairment health care economics and organizations media_common Health economics business.industry Research Health Policy Public health Health services research Health technology Mild cognitive impairment Early diagnosis Cost-effectiveness business Welfare Alzheimer’s disease
Zdroj:	Cost Effectiveness and Resource Allocation, Vol 19, Iss 1, Pp 1-10 (2021) Cost Effectiveness and Resource Allocation : C/E
ISSN:	1478-7547
Popis:	Background Amyloid positron emission tomography (PET) makes it possible to diagnose Alzheimer’s disease (AD) in its prodromal phase including mild cognitive impairment (MCI). This study evaluated the cost-effectiveness of including amyloid-PET for assessing individuals with MCI. Methods The target population was 60-year-old patients who were diagnosed with MCI. We constructed a Markov model for the natural history of AD with the amyloid positivity (AP). Because amyloid-PET can detect the AP MCI state, AD detection can be made faster by reducing the follow-up interval for a high-risk group. The health outcomes were evaluated in quality-adjusted life years (QALYs) and the final results of cost-effectiveness analysis were presented in the form of the Incremental Cost-Effectiveness Ratio (ICER). To handle parameter uncertainties, one-way sensitivity analyses for various variables were performed. Results Our model showed that amyloid-PET increased QALYs by 0.003 in individuals with MCI. The estimated additional costs for adopting amyloid-PET amounted to a total of 1250 USD per patient when compared with the cost when amyloid-PET is not adopted. The ICER was 3,71,545 USD per QALY. According to the sensitivity analyses, treatment effect of Donepezil and virtual intervention effect in MCI state were the most influential factors. Conclusions In our model, using amyloid-PET at the MCI stage was not cost-effective. Future advances in management of cognitive impairment would enhance QALYs, and consequently improve cost-effectiveness.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a9d8b0e3e1a3e8ad2c8a724ae4d25eb https://doaj.org/article/ef9c1e9b5c1c43019c18425fb4eee3ff Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.